JP6642887B2 - アルファヘリックスを模倣した大環状ペプチドミメティック - Google Patents

アルファヘリックスを模倣した大環状ペプチドミメティック Download PDF

Info

Publication number
JP6642887B2
JP6642887B2 JP2016560695A JP2016560695A JP6642887B2 JP 6642887 B2 JP6642887 B2 JP 6642887B2 JP 2016560695 A JP2016560695 A JP 2016560695A JP 2016560695 A JP2016560695 A JP 2016560695A JP 6642887 B2 JP6642887 B2 JP 6642887B2
Authority
JP
Japan
Prior art keywords
group
amino acid
macrocyclic
substituted
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016560695A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017513826A5 (enExample
JP2017513826A (ja
Inventor
ルディ ファサン
ルディ ファサン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Rochester
Original Assignee
University of Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Rochester filed Critical University of Rochester
Publication of JP2017513826A publication Critical patent/JP2017513826A/ja
Publication of JP2017513826A5 publication Critical patent/JP2017513826A5/ja
Application granted granted Critical
Publication of JP6642887B2 publication Critical patent/JP6642887B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2016560695A 2014-04-02 2015-04-01 アルファヘリックスを模倣した大環状ペプチドミメティック Expired - Fee Related JP6642887B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461973994P 2014-04-02 2014-04-02
US61/973,994 2014-04-02
PCT/US2015/023883 WO2015153761A2 (en) 2014-04-02 2015-04-01 Macrocyclic peptidomimetics for alpha-helix mimicry

Publications (3)

Publication Number Publication Date
JP2017513826A JP2017513826A (ja) 2017-06-01
JP2017513826A5 JP2017513826A5 (enExample) 2018-05-17
JP6642887B2 true JP6642887B2 (ja) 2020-02-12

Family

ID=54241434

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016560695A Expired - Fee Related JP6642887B2 (ja) 2014-04-02 2015-04-01 アルファヘリックスを模倣した大環状ペプチドミメティック

Country Status (6)

Country Link
US (1) US10294273B2 (enExample)
EP (1) EP3126375B1 (enExample)
JP (1) JP6642887B2 (enExample)
CN (1) CN106604928A (enExample)
CA (1) CA2944651A1 (enExample)
WO (1) WO2015153761A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102615111B1 (ko) 2016-06-13 2023-12-20 구글 엘엘씨 인간 운영자로의 에스컬레이션
US10827064B2 (en) 2016-06-13 2020-11-03 Google Llc Automated call requests with status updates
US11479581B2 (en) 2017-06-09 2022-10-25 Bristol-Myers Squibb Company Non-chromatographic purification of macrocyclic peptides by a resin catch and release
US11524979B2 (en) 2017-06-15 2022-12-13 University Of Washington Macrocyclic polypeptides
US11339192B2 (en) 2017-10-04 2022-05-24 Ohio State Innovation Foundation Bicyclic peptidyl inhibitors
CN111447941B (zh) 2017-10-27 2023-10-31 俄亥俄州国家创新基金会 用于细胞内递送装订肽的多肽缀合物
EP3746105A4 (en) 2018-01-29 2022-05-18 Ohio State Innovation Foundation CYCLIC PEPTIDYLIN HIBITORS OF THE CAL-PDZ-BINDING DOMAIN
WO2019165183A1 (en) 2018-02-22 2019-08-29 Entrada Therapeutics, Inc. Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy
WO2019217682A1 (en) 2018-05-09 2019-11-14 Ohio State Innovation Foundation Cyclic cell-penetrating peptides with one or more hydrophobic residues
WO2020227313A1 (en) 2019-05-06 2020-11-12 Google Llc Automated calling system
US11158321B2 (en) 2019-09-24 2021-10-26 Google Llc Automated calling system
US12080285B2 (en) 2020-03-20 2024-09-03 Google Llc Semi-delegated calling by an automated assistant on behalf of human participant
US11303749B1 (en) 2020-10-06 2022-04-12 Google Llc Automatic navigation of an interactive voice response (IVR) tree on behalf of human user(s)
WO2023107353A2 (en) * 2021-12-10 2023-06-15 Merck Sharp & Dohme Llc P53 peptidomimetic macrocycles
TW202417465A (zh) 2022-08-23 2024-05-01 日商富士軟片股份有限公司 環肽或其鹽及ｍｄｍｘ抑制劑
WO2024054892A1 (en) * 2022-09-09 2024-03-14 Shape Therapeutics Inc. Therapeutic peptides
US12225158B2 (en) 2022-12-15 2025-02-11 Google Llc System(s) and method(s) for implementing a personalized chatbot
JP2026504093A (ja) 2023-01-16 2026-02-03 アンブレツクス・インコーポレイテツド 抗ｃｄ７０抗体薬物コンジュゲート
US12581015B2 (en) 2023-03-21 2026-03-17 Google Llc Automating telephone call(s) on behalf of user(s)
WO2024241086A1 (en) 2023-05-24 2024-11-28 Ambrx, Inc. Pegylated bovine interferon lambda and methods of use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083983B2 (en) * 1996-07-05 2006-08-01 Cancer Research Campaign Technology Limited Inhibitors of the interaction between P53 and MDM2
US8193310B2 (en) * 2004-03-19 2012-06-05 The University Of Queensland Alpha helical mimics, their uses and methods for their production
CA2686827C (en) * 2006-12-14 2014-09-16 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
BRPI0907754A2 (pt) * 2008-02-08 2015-07-21 Aileron Therapeutics Inc Macrociclos peptidomiméticos terapêuticos
US8343760B2 (en) * 2008-06-05 2013-01-01 University Of Maryland, Baltimore p53 activator peptides
CN102203126A (zh) * 2008-09-22 2011-09-28 爱勒让治疗公司 用于制备纯化的多肽组合物的方法
EP2376100B1 (en) * 2009-01-14 2017-10-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CA2774973A1 (en) * 2009-09-22 2011-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
SI2603600T1 (sl) * 2010-08-13 2019-04-30 Aileron Therapeutics, Inc. Peptidomimetični makrocikli
US9029332B2 (en) * 2010-12-15 2015-05-12 The Research Foundation For The State University Of New York Cross-linked peptides and proteins, methods of making same, and uses thereof
US8986953B2 (en) * 2011-01-20 2015-03-24 University Of Rochester Macrocyclic compounds with a hybrid peptidic/non-peptidic backbone and methods for their preparation

Also Published As

Publication number Publication date
US20170037084A1 (en) 2017-02-09
EP3126375B1 (en) 2023-12-13
US10294273B2 (en) 2019-05-21
WO2015153761A2 (en) 2015-10-08
EP3126375A2 (en) 2017-02-08
EP3126375A4 (en) 2018-01-24
CN106604928A (zh) 2017-04-26
WO2015153761A3 (en) 2015-11-26
CA2944651A1 (en) 2015-10-08
JP2017513826A (ja) 2017-06-01

Similar Documents

Publication Publication Date Title
US10294273B2 (en) Macrocyclic peptidomimetics for alpha-helix mimicry
AU2024200512B2 (en) Stabilized peptide-mediated targeted protein degradation
JP6785932B2 (ja) 構築されたポリペプチド特異性のモジュレーション
JP6259861B2 (ja) ビス−スルフヒドリル大環状化系
JP5649825B2 (ja) 安定化させたｐ５３ペプチドおよびその使用法
JP4997293B2 (ja) トリアゾール大環状系
AU2013221433B2 (en) Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
JP7100034B2 (ja) 多環式ペプチド及びそれらの調製方法
JP2015509940A (ja) ペプチドミメティック大環状化合物
WO2012021875A1 (en) Peptidomimetic macrocycles with triazole linkers
JP2012509902A (ja) 改善された特性を有するペプチド模倣大環状分子
WO2014110420A1 (en) Peptidomimetic compounds
WO2017223207A1 (en) Cyclic peptide inhibitors of hedgehog proteins
JP2024501019A (ja) Ｓｏｓの架橋ヘリックス二量体模倣体およびそれを使用する方法
EP4063380A1 (en) Inhibitors of the wnt signaling pathway and uses thereof
JP5657594B6 (ja) トリアゾール大環状系
HK1137184B (en) Bis-sulfhydryl macrocyclization systems
AU2012203906A1 (en) Triazole macrocycle systems

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180330

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180330

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190520

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190611

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190918

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190918

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20191008

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191203

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191223

R150 Certificate of patent or registration of utility model

Ref document number: 6642887

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees